Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | geranylgeranyl diphosphate synthase 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | geranylgeranyl pyrophosphate synthase, putative | geranylgeranyl diphosphate synthase 1 | 300 aa | 317 aa | 21.4 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative | 0.008 | 0.042 | 0.5 |
Echinococcus multilocularis | fk506 binding protein | 0.008 | 0.042 | 0.187 |
Trichomonas vaginalis | fk506-binding protein, putative | 0.008 | 0.042 | 0.5 |
Schistosoma mansoni | immunophilin | 0.008 | 0.042 | 0.187 |
Plasmodium falciparum | peptidyl-prolyl cis-trans isomerase FKBP35 | 0.008 | 0.042 | 0.5 |
Entamoeba histolytica | peptidyl-prolyl cis-trans isomerase, FKBP-type, putative | 0.008 | 0.042 | 0.5 |
Echinococcus multilocularis | geranylgeranyl pyrophosphate synthase | 0.0127 | 0.2245 | 1 |
Mycobacterium ulcerans | FK-506 binding protein, peptidyl-prolyl cis-trans isomerase | 0.008 | 0.042 | 0.5 |
Echinococcus multilocularis | peptidyl prolyl cis trans isomerase FKBP4 | 0.008 | 0.042 | 0.187 |
Trichomonas vaginalis | peptidylprolyl isomerase, putative | 0.008 | 0.042 | 0.5 |
Giardia lamblia | FKBP-type peptidyl-prolyl cis-trans isomerase | 0.008 | 0.042 | 0.5 |
Echinococcus granulosus | peptidyl prolyl cis trans isomerase FKBP1A | 0.008 | 0.042 | 0.187 |
Echinococcus granulosus | peptidyl prolyl cis trans isomerase FKBP4 | 0.008 | 0.042 | 0.187 |
Leishmania major | polyprenyl synthase, putative | 0.0127 | 0.2245 | 1 |
Chlamydia trachomatis | peptidyl-prolyl cis-trans isomerase | 0.0261 | 0.737 | 0.5 |
Trypanosoma cruzi | polyprenyl synthase, putative | 0.0127 | 0.2245 | 1 |
Trypanosoma brucei | peptidyl-prolyl cis-trans isomerase, putative | 0.008 | 0.042 | 0.5 |
Echinococcus granulosus | geranylgeranyl pyrophosphate synthase | 0.0127 | 0.2245 | 1 |
Brugia malayi | geranylgeranyl pyrophosphate synthetase | 0.0127 | 0.2245 | 1 |
Loa Loa (eye worm) | FKBP-type peptidyl-prolyl cis-trans isomerase-12 | 0.008 | 0.042 | 0.187 |
Entamoeba histolytica | peptidyl-prolyl cis-trans isomerase, FKBP-type , putative | 0.008 | 0.042 | 0.5 |
Toxoplasma gondii | peptidyl-prolyl cis-trans isomerase, FKBP-type domain-containing protein | 0.0261 | 0.737 | 0.5 |
Loa Loa (eye worm) | geranylgeranyl pyrophosphate synthetase | 0.0127 | 0.2245 | 1 |
Trichomonas vaginalis | peptidylprolyl isomerase, putative | 0.008 | 0.042 | 0.5 |
Loa Loa (eye worm) | FKBP5 protein | 0.008 | 0.042 | 0.187 |
Trichomonas vaginalis | immunophilin, putative | 0.008 | 0.042 | 0.5 |
Schistosoma mansoni | geranylgeranyl pyrophosphate synthase | 0.0127 | 0.2245 | 1 |
Giardia lamblia | 70 kDa peptidylprolyl isomerase, putative | 0.008 | 0.042 | 0.5 |
Schistosoma mansoni | immunophilin FK506 binding protein FKBP12 | 0.008 | 0.042 | 0.187 |
Plasmodium vivax | 70 kDa peptidylprolyl isomerase, putative | 0.008 | 0.042 | 0.5 |
Trypanosoma cruzi | polyprenyl synthase, putative | 0.0127 | 0.2245 | 1 |
Schistosoma mansoni | immunophilin | 0.008 | 0.042 | 0.187 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.38 uM | Inhibition of recombinant GGDPS (unknown origin) assessed as decrease in radiolabeld GGPP level using FPP and [14C]IPP as substrate treated with enzyme for 10 mins prior to substrate challenge for 30 mins by liquid scintillation counting analysis | ChEMBL. | 24726306 |
IC50 (binding) | = 79 uM | Inhibition of recombinant FDPS (unknown origin) assessed as decrease in radiolabeld GGPP level using GPP and [14C]IPP as substrate treated with enzyme for 10 mins prior to substrate challenge for 30 mins by liquid scintillation counting analysis | ChEMBL. | 24726306 |
IC50 (binding) | = 400 uM | Inhibition of recombinant FTase (unknown origin) assessed as decrease in prenylated fluorescent peptides level using dansyl-GCVLS and FPP as substrate after 1 hr by HPLC-fluorescence detection analysis | ChEMBL. | 24726306 |
Inhibition (binding) | Inhibition of GGDPS in human RPMI-8226 cells assessed as disruption of monoclonal protein trafficking by measuring accumulation of intracellular lambda light chain at 10 uM after 48 hrs by ELISA | ChEMBL. | 24726306 | |
Inhibition (binding) | Inhibition of GGDPS in human RPMI-8226 cells assessed as increase in intracellular FPP level by measuring FTase-1-mediated FPP incorporation into fluorescent GCVLS peptide at 1 uM after 24 hrs by reverse phase HPLC analysis | ChEMBL. | 24726306 | |
Inhibition (binding) | Inhibition of GGDPS in human RPMI-8226 cells assessed as disruption of Rap1a geranylgeranylation at 1 uM after 48 hrs by western blot analysis | ChEMBL. | 24726306 | |
Inhibition (binding) | Inhibition of GGDPS in human RPMI-8226 cells assessed as disruption of Rab6 geranylgeranylation at 10 uM after 48 hrs by western blot analysis | ChEMBL. | 24726306 | |
Inhibition (binding) | Inhibition of GGDPS in human RPMI-8226 cells assessed as disruption of Rap1a geranylgeranylation at 10 uM after 48 hrs by western blot analysis in presence of 1 mM mevalonate | ChEMBL. | 24726306 | |
Inhibition (binding) | Inhibition of GGDPS in human RPMI-8226 cells assessed as disruption of Rap1a geranylgeranylation at 10 uM after 48 hrs by western blot analysis | ChEMBL. | 24726306 | |
Inhibition (binding) | Inhibition of GGDPS in human RPMI-8226 cells assessed as decrease in intracellular GGPP level by measuring GGTase-1-mediated GGPP incorporation into fluorescent GCVLL peptide at 1 uM after 24 hrs by reverse phase HPLC analysis | ChEMBL. | 24726306 | |
Inhibition (binding) | Inhibition of GGDPS in human RPMI-8226 cells assessed as disruption of Rap1a geranylgeranylation at 10 uM after 48 hrs by western blot analysis in presence of 10 uM GGPP | ChEMBL. | 24726306 | |
Inhibition (binding) | Inhibition of GGDPS in human RPMI-8226 cells assessed as disruption of Rap1a geranylgeranylation at 10 uM after 48 hrs by western blot analysis in presence of 10 uM FPP | ChEMBL. | 24726306 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.